We speculate that AM and RPR suppressed TGF-β1/PI3K/Akt, MAPK, and VEGF signaling pathways by targeting these pharmacological targets, subsequently ameliorating ECM deposition and inflammation in IPF. Here, TGFB1 is linked to idiopathic interstitial pneumonia.